Fore Biotherapeutics (Series D-2)
Funding Details
- Awarder
- Inbox
- Date Award
- May 22, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $38,000,000
Company Info
- Traction
- FORE Biotherapeutics has raised a total of $113 million in the Series D financing, with significant investor backing and promising early clinical data for plixorafenib.
- Company Description
- Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
- Market
- Oncology
- Location
- Philadelphia, Pennsylvania, United States
- Coinvestors
- SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, 3B Future Health Fund